Genitourinary Collaboration and Licensing Deals 2016-2026

Key Benefits

✔ Benchmark against 319 genitourinary partnering deals – Access real-world collaboration and licensing activity to identify relevant precedents and comparable transactions.

✔ Benchmark genitourinary deal financials – Analyze disclosed headline values, upfront payments, milestones and royalty rates and investigate the individual transactions behind the benchmarks.

✔ Identify prospective partners and leading dealmakers – Discover companies with demonstrated interest in genitourinary assets, technologies, therapeutic indications and relevant stages of development.

✔ Compare activity across the genitourinary landscape – Analyze dealmaking by therapeutic indication and target, development stage, technology type, deal type, industry sector and company.

✔ Find the most relevant comparable transactions – Move beyond broad averages to identify deals involving similar indications, targets, technologies, development stages and partnering structures.

✔ Understand how genitourinary deals are structured – Examine licensing rights, development responsibilities, exclusivity, IP, commercialization rights, milestones, royalties and other important transaction provisions.

✔ Learn from real contract documents – Where publicly available, review underlying agreements to understand how rights, obligations, financial terms and other negotiated provisions have been documented.

✔ Apply the intelligence to your own genitourinary opportunity – Qualifying customers may also be eligible for a Customized Executive Partnering Briefing focused on their own asset, indication, target, technology, prospective partners or transaction objectives.

Executive Summary

 

Chapter 1 – Introduction

 

Chapter 2 – Trends in genitourinary dealmaking

 

2.1. Introduction

2.2. Genitourinary partnering over the years     

2.3. Genitourinary partnering by deal type

2.4. Genitourinary partnering by industry sector

2.5. Genitourinary partnering by stage of development

2.6. Genitourinary partnering by technology type

2.7. Genitourinary partnering by therapeutic indication

 

Chapter 3 – Financial deal terms for genitourinary partnering

 

3.1. Introduction

3.2. Disclosed financials terms for genitourinary partnering

3.3. Genitourinary partnering headline values

3.4. Genitourinary deal upfront payments

3.5. Genitourinary deal milestone payments

3.6. Genitourinary royalty rates

 

Chapter 4 – Leading genitourinary deals and dealmakers

 

4.1. Introduction

4.2. Most active in genitourinary partnering

4.3. List of most active dealmakers in genitourinary    

4.4. Top genitourinary deals by value

 

Chapter 5 – Genitourinary contract document directory

                                            

5.1. Introduction

5.2. Genitourinary partnering deals where contract document available

 

Chapter 6 – Genitourinary dealmaking by therapeutic target

 

6.1. Introduction

6.2. Deals by genitourinary therapeutic target

 

Deal directory

 

Deal directory – Genitourinary deals by company A-Z

Deal directory – Genitourinary deals by technology type

 

Deal type definitions

 

About Biopharma Research Ltd

 

Current Partnering

Current Agreements

Recent report titles from Current Partnering

 

Table of figures

 

Figure 1: Genitourinary partnering since 2016

Figure 2: Genitourinary partnering by deal type since 2016

Figure 3: Genitourinary partnering by industry sector since 2016

Figure 4: Genitourinary partnering by stage of development since 2016

Figure 5: Genitourinary partnering by technology type since 2016

Figure 6: Genitourinary partnering by indication since 2016

Figure 7: Genitourinary deals with a headline value

Figure 8: Genitourinary deals with upfront payment values

Figure 9: Genitourinary deals with milestone payment

Figure 10: Genitourinary deals with royalty rates

Figure 11: Active genitourinary dealmaking activity since 2016

Figure 12: Top genitourinary deals by value since 2016

Pricing options

• $3,995: single-user (encrypted file - one user/device)
• $5,995: multi-user (encrypted file - up to 5 users/devices)
• $7,995: company (unencrypted file)

Single and Multi-user license files are encrypted PDF documents. Details of how to access using Javelin3 PDF Reader will be provided at report delivery.

Company license files are not encrypted and can be accessed using a PDF Reader.

A full explanation of license type definitions can be found here.

 

Our guarantee

 

Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.

 

Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)

 

Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.

 

Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by Evalon.

 

Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

20/20 BioLabs, Abbott Laboratories, Abbvie, Acer Therapeutics, Acerus, Acurx Pharmaceuticals, AdaptivEndo, Advanz Pharma, Akcea Therapeutics, Akebia Therapeutics, Alberta Health Services, Albert Einstein College of Medicine, Alexion Pharmaceuticals, Algernon Pharmaceuticals, Alio Medical, AliveCor, Alivio Therapeutics, Allecra Therapeutics, Allergan, Alloy Therapeutics, Alnylam Pharmaceuticals, Altasciences, Altavant Sciences, AM-Pharma, Ambry Genetics, American Lung Association, American Renal Associates, American Urological Association, Amerigen Pharmaceuticals, Amgen, Amicus Therapeutics, Ampio Pharmaceuticals, Amplity Health, Angion Biomedica, Antares Pharma, Anteris Bio, Anthem, Apellis Pharmaceuticals, Aquestive Therapeutics, Aquinox Pharmaceuticals, Arch Biopartners, Ardelyx, Arena Pharmaceuticals, Arrevus, Ascend Clinical, ASC Therapeutics, Asieris Pharmaceuticals, ASKA Pharmaceuticals, Aspect Biosystems, Assistance Publique-Hôpitaux de Paris, Astek Diagnostics, Astellas Pharma, AstraZeneca, Astute Medical, Aurinia Pharmaceuticals, AWAK Technologies, Ayogo Health, Aziyo Biologics, Baxter International, Bayer, Baylor Health Care System, Beacon Discovery, Beckman Coulter, Beijing Mabworks Biotech, BenevolentAI, Beth Israel Deaconess Medical Center, Biim Ultrasound, Bio-Techne, BIOASTER, Biocoat, Biomedical Advanced Research and Development Authority, bioMerieux, Bioqube Ventures, BioSerenity, Blacksmith Medicines, Blue Cross Blue Shield Association, Blue Water Biotech, Boehringer Ingelheim, Bridge Medicines, Brigham and Women's Hospital, BrightInsight, Bristol-Myers Squibb, Caelum Biosciences, Caldera Pharmaceuticals, Calliditas Therapeutics, CAMP4 Therapeutics, Cantex Pharmaceuticals, Cara Therapeutics, CARB-X, Cardio Renal Society of America, CareDx, CB2 Therapeutics, CELLINK, Centogene, ChemoCentryx, China Medical System, Chinook Therapeutics, Cigna Healthcare, CJ Corp, Cleveland Clinic, Climb Bio, Clinical Consultants International, Clinical Laserthermia Systems (CLS), CloudCath, Cogentix Medical, Columbia University, Cook Biotech, Corino Therapeutics, Cornell University, Creative Medical Technologies, Cricket Health, CromSource, CrossBay Medical, CSL, CytoSorbents, Dalton Pharma Services, Danish Innovation Fund, Datavant, DaVita, Debiopharm, Defense Threat Reduction Agency, DemeTECH, Department of Veterans Affairs, Dialco Medical, Dicerna Pharmaceuticals, DILIsym Services, Dimerix Biosciences, Diurnal, Drexel University, Duchesnay, Ecole Polytechnique Federale de Lausanne, eGenesis, EirGen Pharma, Eledon Pharmaceuticals, Elexopharm, Eliaz Therapeutics, Eli Lilly, Enable Injections, Enteris Biopharma, Enzyvant Science, Epigen Biosciences, Erasmus University Medical Center, Erlangen University Hospital, Eton Pharmaceuticals, Eurofins Scientific, Everest Medicines, Eversana, Evestra, Evotec, Exagen Diagnostics, ExCEEd Orphan, Ferring Pharmaceuticals, Fimbrion Therapeutics, FirstString Research, Flagship Pioneering, Forendo Pharma, Fortress Biotech, Fosun Pharmaceutical, Foundation for International Urogynecological Assistance, Frazier Healthcare Ventures, Frenova Renal Research, Fresenius, Fresenius Kabi Pharmaceuticals, Fresenius Medical Care, Fuji Yakuhin, Fundacion Progreso y Salud, Gedeon Richter, Geisinger Medical Center, Genewiz, Genexo, George Clinical, Gilead Sciences, Goldfinch Bio, Google, Great Bay Bio, GSK, Guangzhou Boji Medical Biotechnological, Hangzhou Zhongmei Huadong Pharmaceutical, Harvard Stem Cell Institute, Harvard University, Health Logic Interactive, Helix BioPharma, HemoCleanse, Henlius Biotech, HHS Technology Group, HIBio, Horizon Therapeutics, Humana, HydroCision, Hyloris Pharmaceuticals, Ibidi, Icahn School of Medicine at Mount Sinai, Ideal Medical Solutions, IGAN Biosciences, Ilias Biologics, Immedica, ImmuneID, ImpediMed, Innovation Network Corporation, Innovus Pharmaceuticals, Insilico Medicine, IntelGenx, Intelligent Scopes, IntrinsiQ, Inventia Healthcare, Invitae, InVivo, Ion Channel Innovations, Ionis Pharmaceuticals, Itochu, Jana Care, Janssen Pharmaceuticals, Janssen Research & Development, Japan Tobacco, JCR Pharmaceuticals, Johns Hopkins University, Jolt Health, JSR, Juventas Therapeutics, Kahn-Sagol-Maccabi, Kaken Pharmaceutical, Karolinska Institute, KBI BioPharma, Keryx Biopharmaceuticals, Key Technologies, Kezar Life Sciences, Kumamoto University, Kyorin Pharmaceutical, Kyowa Hakko Kirin, Kyowa Hakko Kogyo, Laborie Medical Technologies, Lavasta Pharma, Leiden University, Lifeline Vascular Care, LifeStrands Genomics, Locus Biosciences, Lupus Foundation of America (LFA), Lupus Research Alliance, Lupus Therapeutics, Luqa Pharmaceuticals, Marathon Medical, Massachusetts General Hospital, Mathematica, Mauna Kea Technologies, Mayo Clinic, Maze Therapeutics, Medeologix, MediBeacon, Medical University South Carolina, Medice Arzneimittel Pütter, MedImmune, Medinova, Medipal Holdings, Medison Pharma, Medline Industries, Melinta Therapeutics, Memorial Sloan Kettering Cancer Center, Menarini, Merck Animal Health, Merck Sharpe & Dohme, Merz, Mesh Bio, Metabolon, MetaSight Diagnostics, Methuselah Foundation, Metrion Biosciences, Michigan Medicine, MicrobeDx, Mironid, Mitobridge, Morehouse School of Medicine, MorphoSys, Mount Sinai Health System, MultiOmic Health, Murdoch Childrens Research Institute, Myovant Sciences, Nanostics Precision Health, NanoVibronix, Nantes University, Nashville Biosciences, National Institute of Allergy and Infectious Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, National Institutes of Health Clinical Center, National Kidney Foundation, National Research Council Canada, NCPC GeneTech, Neokidney, Nephria Bio, Neptune Technologies & Bioressources, Nestle Health Science, NeuralStem, Nicoya, Nkarta Therapeutics, NMI Natural and Medical Sciences Institute, Nosopharm, Novartis, Novo Integrated Sciences, Novo Nordisk, Numares, Oklahoma Medical Research Foundation, OmniVision Technologies, One Biosciences, Onegevity, OpGen, OPKO Health, Organovo, OrsoBio, OSE Immunotherapeutics, Ospedale San Raffaele, Otsuka, Outpost Medicine, Outset Medical, Palette Life Sciences, Palleon Pharmaceuticals, Panion & BF Biotech, Par Pharmaceutical, PatenSee, Patheon N.V., Penn State College of Medicine, Perlara, Pharmacological research Institute Mario Negri, Pherecydes Pharma, Pierre Fabre, Pivotal bioVenture Partners, Poiesis Medical, PPD, Precision Image Analysis, Procept BioRobotics, Promepla, Promethera Biosciences, Prometic Life Sciences, Protalix BioTherapeutics, Proteomics International, Purdue Pharma, PureTech Health, PX Therapeutics, Pythagoras Medical, Q32 Bio, Quebec Urological Association Foundation, Quimica Europea, Quotient Therapeutics, Rambam Medical Center, REACH Kidney Care, Reata Pharmaceuticals, Rebiotix, ReCor Medical, Rectify Pharmaceuticals, Rediscovery Life Sciences, Regulus Therapeutics, Relief Therapeutics, Renalys Pharma, RenalytixAI, Resverlogix, ReviR Therapeutics, Roche, Roche Diagnostics, Rockwell Medical, ROi (Resource Optimization & Innovation), Roivant Sciences, ROKIT Healthcare, Royal Children’s Hospital, Samsung Bioepis, SandboxAQ, Sanguina, Saniona, SanReno Therapeutics, Sarfez Pharmaceuticals, Satellite Healthcare, Scanwell Health, Scohia Pharma, Scynexis, Secarna Pharmaceuticals, Selecta Biosciences, Selexis, Sequentify, Shanghai Haini Pharmaceutical, Siemens Healthineers, Silence Therapeutics, Singapore General Hospital, SinoMab Bioscience, Sinovant Sciences, Somatus, SOM Biotech, Sonacare Medical, Specialty Renal Products, Spectrum Pharmaceuticals, Spero Therapeutics, Sphingotec, Spruce Biosciences, STADA Arzneimittel, Stanford University, Sumitomo Dainippon Pharma, Sumitomo Pharmaceuticals, Sumitovant Biopharma, Sun Pharmaceutical, Suzhou Sinovent Pharmaceuticals, Swedish Orphan Biovitrum, Swixx Biopharma, SyMap Medical, Sysmex America, TaiGen Biotechnology, Takeda Pharmaceutical, Teijin, Telara Pharma, Telix Pharmaceuticals, Terumo Blood and Cell Technologies, Tetra Bio-Pharma, Teva Pharmaceutical Industries, The Medicines Company, The United Laboratories, Thoeris, Thorne Research, TONIX Pharmaceuticals, toSense, Travere Therapeutics, Trestle Biotherapeutics, Tufts Medical Center, twoXAR, TxCell, Ubiquigent, Unicycive Therapeutics, Unilife, University of Arkansas, University of Bristol, University of California, San Diego, University of California Berkeley, University of California San Francisco, University of Cambridge, University of Glasgow, University of Houston, University of Massachusetts Medical School, University of Miami, University of Michigan, University of Pennsylvania, University of Sheffield, University of Texas, University of Texas at El Paso, University of Toronto, University of Utah, University of Western Ontario, UpScriptHealth, Ur24Technology, UroGen Pharma, Urotronic, Urovant Sciences, US Air Force, US Army Medical Research Institute of Infectious Diseases, Vanderbilt University, Vaneltix Pharma, Varian Medical Systems, Variant Bio, VenatoRx, Vensica Medical, Ventus Therapeutics, Verana Health, Vertex Pharmaceuticals, Viatris, Vifor-Fresenius Medical Care Renal Pharma, Vifor Pharma, Vinnova, VisiQuate, Vizient, vTv Therapeutics, Weill Cornell Medical College, Winhealth Pharma Group, Worldwide Clinical Trials, Wuxi Apptec Laboratory Services, Xisle Pharma Ventures Trust, Xortx Therapeutics, Yeda Research and Development Company, Yonsei University Severance Hospital, Zai Lab, Zhejiang Ausun Pharmaceutical, Zifo, Zydus Cadila, ZyVersa Therapeutics

About Current Partnering

A definitive, evidence-based approach to dealmaking intelligence

Current Partnering is the industry-leading provider of pharmaceutical and biotech dealmaking intelligence, delivering a clear, structured, and evidence-based view of how partnerships are designed, negotiated, and executed in practice.

Our reports combine comprehensive deal coverage, structured data analysis, and contract-level insight, enabling a deeper understanding of how financial terms, rights, and responsibilities are defined across real-world transactions.

All reports are updated every six months, ensuring users have access to the latest deal activity, trends, and market developments.

---

Our methodology

Built on a continuously updated proprietary database

All analysis is underpinned by Current Agreements, our proprietary deals and alliances database which is updated daily by our analysts as new transactions are announced globally.

Deal records are continuously reviewed and enriched as additional information becomes available, ensuring accuracy, completeness, and relevance.

---

Comprehensive and verifiable data sourcing

Deal data is sourced from publicly available industry disclosures, including:

• Company press releases and announcements
• SEC filings and equivalent regulatory disclosures
• Company and investor presentations
• Conference materials and company websites

All sources are captured and referenced, enabling full transparency and user verification.

---

Broad coverage across deal types and structures

Current Partnering provides comprehensive coverage across a wide range of deal types, including but not limited to:

• Licensing and co-development
• Research and collaborative R&D
• Manufacturing, supply, and distribution
• Commercialisation and co-promotion
• Equity investments, joint ventures, and asset transactions
• Options, royalties, and financing agreements

This breadth ensures a complete view of how partnerships are structured across the life sciences sector.

---

Structured, standardised analysis

Every deal is analysed using a consistent framework, capturing (where disclosed):

• Financial terms — including upfront payments, milestones, and royalties
• Rights allocation — development, manufacturing, and commercialization responsibilities
• Deal structure — exclusivity, territorial scope, and agreement type
• Contractual provisions — clauses defining risk, control, and value-sharing

Each deal record is fully categorised, including data fields such as:

• Therapy area and technology type
• Stage of development
• Asset type and deal components
• Geographic scope and exclusivity
• Source documentation, including press releases and SEC filings

---

Financial normalisation for comparability

All financial values are standardised to USD using the exchange rate at the time of deal announcement, enabling consistent comparison of deal terms across geographies.

---

Contract-level insight

Where available, reports include direct access to underlying agreement documents, providing visibility into how deals are constructed in practice.

This enables users to understand:

• How financial mechanisms are defined and triggered
• How responsibilities are operationalised between parties
• How flexibility, risk, and control are allocated within agreements

---

Designed for real-world application

Current Partnering reports are built to support business-critical decision-making across the life sciences ecosystem, including:

• Pharmaceutical and biotech companies — benchmarking deals, structuring transactions, and supporting licensing strategy
• Investment firms and venture capital — assessing deal benchmarks, valuation expectations, and partner behaviour
• Advisory, legal, and consulting firms — supporting client engagements with real-world precedent and contract-level insight

Common use cases include:

• Benchmarking comparable transactions
• Supporting valuation and deal structuring
• Preparing for negotiations
• Evaluating potential partners
• Informing internal strategy with real-world evidence

---

A trusted industry reference

With a long track record in the sector, Current Partnering is relied upon by leading pharmaceutical companies, emerging biotechs, investors, and advisory firms as a trusted source of dealmaking intelligence.

By combining proprietary data, rigorous methodology, and contract-level insight, our reports provide a reliable and authoritative foundation for understanding how deals are structured, negotiated, and valued.